William Blair Analysts Increase Earnings Estimates for NBIX

Key Points

• William Blair analysts have raised their Q3 2025 EPS estimate for Neurocrine Biosciences to $1.33, up from $1.25, while the full-year consensus estimate stands at $4.28 per share.
• Various firms have initiated coverage on Neurocrine Biosciences with a majority issuing buy ratings, and the average target price set at $160.90.
• The stock has shown strong performance, with a recent EPS of $1.06 beating estimates, and an increase in revenue of 16.5% year-over-year.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Investment analysts at William Blair upped their Q3 2025 EPS estimates for Neurocrine Biosciences in a research note issued on Thursday, July 31st. William Blair analyst M. Minter now forecasts that the company will post earnings per share of $1.33 for the quarter, up from their prior forecast of $1.25. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share.

Several other research firms have also weighed in on NBIX. The Goldman Sachs Group initiated coverage on shares of Neurocrine Biosciences in a research note on Thursday, July 10th. They issued a "buy" rating and a $182.00 price objective for the company. Truist Financial started coverage on shares of Neurocrine Biosciences in a report on Monday, July 21st. They issued a "buy" rating and a $163.00 price target for the company. HC Wainwright dropped their price objective on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating on the stock in a report on Tuesday, April 22nd. Wedbush increased their price objective on shares of Neurocrine Biosciences from $137.00 to $141.00 and gave the stock an "outperform" rating in a research report on Thursday. Finally, Canaccord Genuity Group boosted their target price on Neurocrine Biosciences from $158.00 to $160.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $160.90.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $128.91 on Monday. The firm has a market cap of $12.79 billion, a PE ratio of 38.14, a price-to-earnings-growth ratio of 1.11 and a beta of 0.25. Neurocrine Biosciences has a 52-week low of $84.23 and a 52-week high of $157.40. The business's 50 day moving average price is $128.26 and its two-hundred day moving average price is $120.74.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.98 by $0.08. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%. The company had revenue of $687.50 million for the quarter, compared to the consensus estimate of $653.09 million. During the same period in the previous year, the business earned $1.63 EPS. The firm's revenue was up 16.5% compared to the same quarter last year.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of institutional investors have recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. boosted its stake in shares of Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company's stock worth $25,000 after buying an additional 135 shares during the last quarter. Huntington National Bank lifted its holdings in Neurocrine Biosciences by 73.5% during the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock worth $31,000 after acquiring an additional 97 shares during the period. WPG Advisers LLC purchased a new position in Neurocrine Biosciences in the first quarter worth $32,000. Smallwood Wealth Investment Management LLC purchased a new position in Neurocrine Biosciences in the first quarter worth $34,000. Finally, GeoWealth Management LLC grew its stake in Neurocrine Biosciences by 65.4% in the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company's stock valued at $35,000 after purchasing an additional 102 shares during the period. 92.59% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 9,613 shares of the firm's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total transaction of $1,157,212.94. Following the transaction, the director directly owned 514,596 shares in the company, valued at approximately $61,947,066.48. This trade represents a 1.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ingrid Delaet sold 457 shares of the company's stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total transaction of $61,695.00. Following the completion of the sale, the insider owned 4,730 shares of the company's stock, valued at approximately $638,550. The trade was a 8.81% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 90,251 shares of company stock worth $11,672,602. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.